Jazz Pharmaceuticals plc
In the published model solve dated 2026-Q2, anchored at $257.10, Jazz Pharmaceuticals plc (JAZZ) is priced for +7.2% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Jazz Pharmaceuticals is a specialty drugmaker anchored by its oxybate sleep franchise (Xywav and Xyrem) and a growing neuroscience and oncology portfolio including Epidiolex and Rylaze, with the company describing Xywav as positioned to remain ⟦"the #1 branded oxybate treatment for narcolepsy."⟧ • At $224.63 only the forward-growth method reaches the price; the asset and earnings-power methods say richly valued, because reported earnings are distorted by heavy acquisition-related amortization
Is JAZZ overvalued? See what's priced in →
555 institutional managers reported holding JAZZ in 13F filings for the quarter ended 2026-03-31. 81 opened new positions that quarter. Held by Vanguard Group, BlackRock, Capital Group (American Funds), among others. On the short side, 3.9M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
JAZZ's share count grew 4.1% over the past five years even with $706.27M spent on repurchases. It pays no dividend. Cash returned over the past three years: $610.62M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at JAZZ over the trailing three years: 2024: 1 buy totaling $1.44M; 2025: 4 buys totaling $9.99M. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
JAZZ's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +2.2% | -5.3% |
| 2023-11-09 | -12.8% | +3.3% |
| 2024-02-29 | -10.1% | -8.1% |
| 2024-05-03 | -1.3% | -7.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
JAZZ's latest 8-K filings: 2026-07-24 (items 5.07); 2026-05-29 (items 5.02); 2026-05-05 (items 2.02, 9.01); 2026-02-24 (items 2.02, 9.01); 2026-01-12 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.